Moderna (MRNA) EBIT Margin: 2017-2025
Historic EBIT Margin for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -25.59%.
- Moderna's EBIT Margin fell 2183.00% to -25.59% in Q3 2025 from the same period last year, while for Sep 2025 it was -155.15%, marking a year-over-year decrease of 10146.00%. This contributed to the annual value of -121.91% for FY2024, which is 6001.00% down from last year.
- Moderna's EBIT Margin amounted to -25.59% in Q3 2025, which was up 95.99% from -638.73% recorded in Q2 2025.
- In the past 5 years, Moderna's EBIT Margin ranged from a high of 75.02% in Q4 2021 and a low of -972.22% during Q1 2025.
- In the last 3 years, Moderna's EBIT Margin had a median value of -128.99% in 2024 and averaged -361.26%.
- In the last 5 years, Moderna's EBIT Margin spiked by 170,286bps in 2021 and then tumbled by 73,843bps in 2024.
- Quarterly analysis of 5 years shows Moderna's EBIT Margin stood at 75.02% in 2021, then plummeted by 4,395bps to 31.08% in 2022, then slumped by 3,086bps to 0.21% in 2023, then crashed by 12,920bps to -128.99% in 2024, then plummeted by 2,183bps to -25.59% in 2025.
- Its last three reported values are -25.59% in Q3 2025, -638.73% for Q2 2025, and -972.22% during Q1 2025.